TREATMENT COSTS FOR COVID-19 PATIENTS IN A TERTIARY HOSPITAL FROM SERBIA

  1. Predrag S. Sazdanovic
  2. Slobodan Milisavljevic
  3. Dragan R. Milovanovic
  4. Slobodan M. Jankovic
  5. Dejan Baskic
  6. Dragana Ignjatovic Ristic
  7. Dejana Ruzic Zecevic
  8. Aleksandra Tomic Lucic
  9. Natasa Djordjevic
  10. Danijela Jovanovic
  11. Andjelka Stojkovic
  12. Tatjana Lazarevic
  13. Milica Begovic Cvetkovic
  14. Marina J. Kostic
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Introduction

Aim of our study was to identify total costs of COVID-19 inpatients treatment in an upper-middle income country from Southeast Europe.

Methods

This retrospective, observational cost of illness study was performed from National Health Insurance Fund perspective and included a cohort of 118 males and 78 females admitted to COVID-19 ward units of a tertiary center, during the first wave of epidemics.

Results

The median of total costs in the non-survivors’ subgroup (n=43) was 3279.16 Euro (4023.34, 355.20, 9909.61) which is higher than in the survivors (n=153) subgroup 747.10 Euro (1088.21, 46.71, 3265.91). The odds ratio of Charlson Comorbidity Index total score and every 100-Euros increase of patient’s total hospital treatment costs for fatal outcome were 1.804 (95% confidence interval 1.408-2.311, p<0.001) and 1.050 (1.029-1.072, p<0.001), respectively.

Conclusions

Direct medical treatment costs for COVID-19 inpatients represent significant economic burden. The link between increased costs and unfavorable final outcome should be further explored.

Related articles

Related articles are currently not available for this article.